

1 Toward Rapid Sequenced-Based Detection and Characterization of Causative Agents of

2 Bacteremia

3

4 F. Curtis Hewitt\*, Stephanie L. Guertin, Krista L. Ternus, Kathleen Schulte, and Dana R. Kadavy

5

6 Signature Science, LLC, Austin, Texas, United States of America

7

8 \*Corresponding author

9 [chewitt@signaturescience.com](mailto:chewitt@signaturescience.com) (FCH)

10 **Abstract**

11 Rapid pathogen diagnosis and characterization performed by metagenomic DNA sequencing may  
12 permit physicians to better target therapies in order to improve patient outcomes. To this end, a  
13 novel sample-to-answer workflow was assembled to enable rapid clinical detection of causative  
14 pathogens of bacteremia in whole blood utilizing metagenomic sequence data captured by the  
15 MinION. Rapid lysis, nucleic acid purification, host depletion, and genomic DNA library  
16 preparation permitted the detection of multiple bacterial and fungal agents spiked into whole  
17 blood, with sequencing commencing within 40 minutes of sample receipt. A hybrid detection  
18 strategy utilizing targeted PCR detection of specific pathogens of concern was adopted to improve  
19 overall sensitivity. As a proof of concept, primers for relatively long amplicons (~1800 bp) were  
20 selected to enable the specific detection of *Yersinia pestis*. The resulting amplicon library was  
21 spiked onto the same sequencing flow cell used to perform genomic sequencing, permitting  
22 simultaneous pathogen detection via both targeted and untargeted sequencing workflows.  
23 Sensitivities on the order of  $1 \times 10^6$  cells/mL and  $1 \times 10^5$  cells/mL were achieved for untargeted  
24 and targeted detection, respectively, of *Y. pestis* genomes spiked into whole blood. Bacterial and  
25 fungal species present in the ZymoBIOMICS Microbial Community Standard were also detected  
26 when spiked at similar levels. Variable quality of sequence reads was observed between the  
27 transposase-based and ligation-based library preparation methods, demonstrating that the more  
28 time consuming ligation-based approach may be more appropriate for the workflow described  
29 herein. Overall, this approach provides a foundation from which future point of care platforms  
30 could be developed to permit characterization of bacteremia within hours of admittance into a  
31 clinical environment.

32

## 33 **Author Summary**

34 Cases of bacteremia in the U.S. present a significant clinical challenge, especially due to rising  
35 rates of antimicrobial resistant strains. Rapid diagnosis of the etiologic pathogen and underlying  
36 drug resistance genetic signatures between the first and second antibiotic dose should improve  
37 patient outcomes and may permit physicians to better target antibiotic therapies without turning to  
38 broad spectrum antibiotics, which may further propagate resistant strains. The methods described  
39 herein have been developed to enhance the real time nature of the MinION sequencer. DNA  
40 sequencing and real time analysis begin within 40 minutes of sample receipt (as opposed to hours  
41 or days for common clinical nucleic acid extraction or blood culture techniques). The incorporation  
42 of sensitivity enhancements, such as methylation-based pulldown of human DNA or PCR targeted  
43 for pathogens of interest, ensures that this assay can detect bacterial blood infections at clinically  
44 relevant levels. The pathogen-agnostic aspect of the assay could one day allow clinicians to  
45 identify any unknown bacterial, fungal, or viral DNA in a sample. Ultimately, this study serves as  
46 an important step toward establishing a pipeline to rapidly detect and characterize pathogens  
47 present in whole blood.

48

## 49 **Introduction**

50 High-throughput next generation sequencing platforms have not made a substantial impact on the  
51 human pathogen clinical diagnostics market despite the disruptive, transformative nature of the  
52 technology<sup>1,2</sup>. Beyond the challenge of achieving regulatory approval, the primary limitations  
53 associated with NGS for clinical diagnostics center largely on cost, throughput (especially time to  
54 answer), and the challenge of data analysis. As the cost of sequencing continues to decrease due

55 to novel technologies and competition in the marketplace<sup>3</sup>, it becomes critical to increase assay  
56 speed and simplify data analysis in order to hasten the incorporation of NGS assays into the  
57 diagnostics marketplace.

58

59 The MinION™ (Oxford Nanopore Technologies, Oxford, UK; ONT) represents an ideal candidate  
60 to achieve rapid high throughput sequencing. The MinION performs single molecule sequencing  
61 via protein nanopores located within a sequencing flow cell that includes accompanying  
62 electronics<sup>4</sup>. This platform has significant appeal due to its simple library preparation, long read  
63 generation, flexible run times, and small footprint. Multiple studies have utilized the MinION to  
64 perform either long read shotgun sequencing capable of agnostic pathogen detection or targeted  
65 amplicon sequencing<sup>5-8</sup>. Sequencing accuracy and throughput have improved with the recent  
66 sequencing chemistries (e.g., R9.4), consistently generating >80% single strand sequence identity  
67 and 5-10 GB of sequence data per 48 hour run at 450 bases/second, according to emerging reports<sup>9</sup>.  
68 While sequencing accuracy remains a potential drawback for clinical adoption, the rapid library  
69 prep (approximately 10 minutes) and real time nature of each sequencing run permit significant  
70 decreases in assay run time compared to other NGS platforms<sup>7,8,10</sup>. ONT also provides a suite of  
71 real time basecalling and metagenomics analysis tools, which promises to decrease the overall  
72 burden associated with bioinformatics analysis of NGS data<sup>11</sup>.

73

74 A quick sample preparation method is required to fully capitalize on the rapid library preparation  
75 and real time sequence analysis provided by the MinION. The workflow developed for this study  
76 incorporates several time saving modifications to minimize total sample preparation time. Analysis  
77 of whole blood presents a significant time savings compared to the generation of cell free fluids

78 (i.e., blood plasma), albeit at the expense of generating significant host background sequence data.  
79 To ensure effective lysis of all potential pathogens present in a sample including viruses, gram  
80 positive and gram negative bacteria, fungal species, and hard-to-lyse bacterial and fungal spores,  
81 a mechanical method to shear cells (i.e., bead beating) was incorporated as a faster and more robust  
82 alternative to chemical lysis<sup>10</sup>. Further time savings were achieved via the use of expedited  
83 methods for DNA purification and pathogen enrichment. These magnetic bead-based pulldown  
84 methods represent a scalable method for purification when compared to column-based kits such  
85 as those produced by Qiagen<sup>12</sup> or differential lysis kits for enrichment such as those produced by  
86 Molzym<sup>13</sup>.

87

88 To assess the assembled workflow, this study utilized a number of potential blood pathogens.  
89 Organisms utilized for testing included a naturally circulating biothreat pathogen (*Y. pestis*),  
90 various additional gram-negative bacteria (e.g., *Salmonella enterica*), several gram-positive  
91 bacteria (e.g., *Staphylococcus aureus*), as well as two fungal species. *Y. pestis*, which typically  
92 infects 1-20 individuals in the U.S. per year<sup>14</sup>, was selected as the main focus of this study due to  
93 the importance of strain-level identification which can be performed by the interrogation of genetic  
94 determinants including nucleotide variants and plasmid content. The diversity within the *Yersinia*  
95 genus also presents a challenge for metagenomic classification as accurate species identification  
96 must be performed to differentiate potential biothreat agents from less-pathogenic near neighbors  
97 (i.e., *Y. pseudotuberculosis*, *Y. enterocolitica*)<sup>15,16</sup>. The sample preparation methodology presented  
98 herein successfully identified the presence of a *Y. pestis* pathogen panel spiked into whole blood  
99 via both shotgun and targeted sequence analysis, albeit at relatively high titer levels. These results

100 suggest a path forward for rapid sample preparation and metagenomic analysis at a throughput  
101 level (sample-to-answer in less than four hours) compatible with the needs of clinical diagnostics.

102

## 103 **Results and Discussion**

### 104 **Workflow Design**

105 The workflow was designed to achieve cell lysis, nucleic acid extraction, pathogen enrichment,  
106 and library preparation in as little time as possible. The underlying goal of this workflow time  
107 compression was to commence real time DNA sequencing and analysis as quickly as possible. The  
108 non-targeted workflow shown in Figure 1 allowed a prepared DNA library to be added to  
109 sequencing flow cells within 40 minutes of sample receipt (or approximately 20 minutes without  
110 pathogen enrichment). Significant time reductions compared to conventional whole blood DNA  
111 extraction methods were achieved via the utilization of the OmniLyse bead beater (ClaremontBio)  
112 for rapid cell lysis and magnetic bead-based approaches for DNA purification and enrichment. The  
113 rapid genomic transposase-based sequencing kit (SQK-RAD002; ONT) was used to prepare  
114 purified DNA for sequencing in approximately 10 minutes, and samples were then sequenced with  
115 the MinION. This portion of the workflow enables the collection of data from all DNA present in  
116 the sample, permitting detection of unexpected or novel pathogens. However, the sensitivity of  
117 this shotgun approach is limited by the amount of host background present in the sample.

118

119 To improve sensitivity for specific pathogens, purified nucleic acids were also subject to targeted  
120 PCR and amplicon library preparation (Figure 1). The amplicon sequencing library was added  
121 directly to the same flow cell without washing away the genomic library, enabling parallel

122 sequencing of the targeted and untargeted library. Real time basecalling (via cloud-based and local  
123 basecalling) and pathogen identification were performed using ONT-released tools. Third party  
124 metagenomic analysis tools were utilized to confirm results and provide additional confidence in  
125 pathogen classifications.

126

## 127 Pathogen Enrichment for Agnostic Detection

128 Host background significantly confounds metagenomic analysis, especially in matrices such as  
129 whole blood, which contains  $>10^6$  nucleated cells/mL. Numerous host depletion or pathogen  
130 enrichment techniques have been reported for metagenomic sequencing of human matrices<sup>12,17</sup>.  
131 Here, we utilized the NEBNext® Microbiome DNA Enrichment Kit (New England Biolabs;  
132 NEB), which utilizes magnetic beads to specifically bind eukaryotic methylation patterns (5-  
133 Methylcytosine in CpG dinucleotides). Enrichment was performed following nucleic acid  
134 purification, as shown in Figure 1. *Y. pestis* culture (Harbin 35 strain) was spiked into human whole  
135 blood at  $2.58 \times 10^6$  cells/mL and processed via the pathogen-agnostic portion of the workflow  
136 (Figure 1) with or without enrichment. Sequencing of each library was carried out for  
137 approximately 16 hours with basecalling and metagenomic analysis via the ONT What's In My  
138 Pot (WIMP) tool, which is based on Kraken<sup>11</sup>. A total of one read in the unenriched sample was  
139 attributed to *Yersinia* out of a total of 4,217 reads (Figure 2A). In the enriched sample, 57 reads  
140 were classified as *Yersinia* out of a total 8,649 reads, providing an overall 28-fold enrichment of  
141 *Yersinia* reads. The NEB enrichment process enabled detection of all bacterial species present in  
142 the Zymo mock community, which was spiked into human whole blood at  $2.9 \times 10^7$  cells/mL  
143 (approximately  $3 \times 10^6$  cells/mL of each species in the community) (Figure 2B). Fungal species  
144 present within the mock community were also observed following enrichment, as expected due to

145 the lack of CpG methylation used to deplete host background DNA<sup>18</sup>. Despite low overall read  
146 counts across these experiments, potentially due to suboptimal DNA input or quality, these data  
147 suggest that host depletion plays a critical role in the overall sensitivity of this workflow.

148

#### 149 Pathogen Enrichment via Simultaneous PCR

150 MinION flow cells are flexible with regard to sequencing different libraries within each flow cell's  
151 48-hour sequencing lifetime. While loading multiple sequencing libraries from different  
152 samples/individuals is possible, carry-over between runs may create false positive detections that  
153 would be problematic for clinical diagnostics. However, preparing different libraries from the  
154 same sample overcomes the issue of contamination. As described in Figure 1, a hybrid  
155 shotgun/targeted approach was devised to permit targeted detection of high-consequence  
156 pathogens at greater sensitivities than possible with the untargeted pathway alone.

157

158 To test this method, a panel of primers specific to the *Y. pestis* genome and various plasmids was  
159 obtained (Table S1)<sup>19-22</sup>. The entire workflow described in Figure 1, including enrichment via the  
160 NEB kit, was performed as described above using human whole blood samples spiked with  
161  $2.58 \times 10^6$  cells/mL *Y. pestis* and approximately  $3 \times 10^6$  cells/mL of each species in the Zymo  
162 mock community. A total of 1  $\mu$ L (~20 ng) of the resulting DNA was subject to PCR using each  
163 primer set. PCR products were verified by gel electrophoresis and purified via AMPure XP beads  
164 (Beckman Coulter). Library preparation was carried out according to manufacturer's instructions  
165 for ligation-based 1D sequencing. The ongoing genomic DNA sequence run was briefly stopped  
166 to permit loading of the amplicon library. Sequencing then resumed with data collection occurring



167 at a significantly higher rate (>1,000 reads per minute) than observed for the genomic library alone  
168 (Figure 3A). At this rate, significant coverage depth (greater than 30x coverage, sufficient for  
169 variant calling) of each amplicon was generated within minutes of sequencer re-initialization.

170

171 A total of 64,980 reads was successfully classified according to species, resulting from both the  
172 targeted and non-targeted aspects of the workflow. More than 14,000 reads, predominantly  
173 resulting from the amplicon sequencing portion of the workflow, were correctly attributed to *Y.*  
174 *pestis* (Figure 3B). The non-targeted portion of the workflow also detected *Yersinia* as well as  
175 every component of the Zymo mock community, albeit at very low sequence depth. Alignment of  
176 reads to the *Y. pestis* genome reveals the representative sequence depth along a portion of the  
177 reference genome compared to the significant sequence depth achieved via amplicon sequencing  
178 (Figure 3C).

179

#### 180 Variant Calling to Differentiate *Y. pestis* Strains

181 The genomic primer sets selected for testing encompass variants permitting the differentiation of  
182 *Y. pestis* strains. The amplicon targeted against the *ail* gene (Table S1) contains a single SNP which  
183 differentiates *Y. pestis* strain Harbin 35 from strain CO92<sup>19</sup>. The amplicon targeted against the  
184 *vasK* gene contains a 1 nt insertion in the Harbin 35 and CO92 strains, which can be used to  
185 differentiate these strains from strain KIM10<sup>20</sup>. To test whether these variants were correctly  
186 identified as part of the amplicon sequencing portion of the workflow, reads were aligned against  
187 the Harbin 35 genome and visualized using IGV (Figure 4). Surprisingly, the variant present near  
188 the *ail* gene (nt 2,998,385) did not conform to the reference genome. Of the 7,121 total reads at

189 this site, 71% contained 2,998,385G, matching those reported in pathogenic strains such as CO92,  
190 and 26% of total reads contained the variant for the reference genome. These data suggest a  
191 potential mixture within the culture, as the 26% variant frequency is significantly higher than the  
192 sequencing error observed in the flanking region. The absence of the *pgm* locus was verified to  
193 ensure that this mixture did not include a pathogenic strain of *Y. pestis* (data not shown)<sup>23</sup>. Of the  
194 3,141 total reads covering the *vasK* amplicon, 96% contained the variant in the reference genome  
195 (4,279,948C). Four hundred and sixteen reads contained a deletion at this location, as would be  
196 expected in the KIM10 strain. However, this is similar to the general indel rate in the flanking  
197 amplicon sequence, suggesting that this is an artifact of the current nanopore sequencing process.  
198 Overall, the current nanopore sequencing chemistry appears to support variant analysis for strain-  
199 level detection, albeit with error rates (especially indels<sup>24</sup>) which could lead to misclassifications.

200

## 201 Data Quality between Library Preparation Methods

202 Significant differences in quality score and sequence length distribution dependent on the library  
203 preparation method were consistently observed across four individual flow cells. Representative  
204 data is shown in Figure 5. In general, significantly higher quality scores were generated using 1D  
205 ligation-based library prep chemistry as opposed to the transposon-based rapid library prep  
206 method). This decrease in quality had a significant impact on the number of reads available for  
207 metagenomic analysis, especially for tools which impose a minimum quality score threshold prior  
208 to analysis, such as ONT's WIMP tool. In line with the disparity in quality scores, the pass/fail  
209 ratio determined during basecalling was significantly higher for the ligation-based prep compared  
210 to the transposase chemistry.

211

212 It is possible that the utilization of input DNA quantities below manufacturer recommendations  
213 for rapid genomic sequencing contributed to lower quality scores; however, the observed pattern  
214 in sequencing quality was observed even when using highly purified pathogen DNA stocks at the  
215 recommended quantity. Under ideal conditions, the rapid library prep method yielded average and  
216 median QScores of 4.8 and 3.8, respectively. The ligation prep method yielded average and median  
217 QScores of 6.9 and 7.1, respectively. This data suggests that the shorter duration and simplified  
218 handling associated with the rapid library prep method may not sufficiently outweigh the decrease  
219 in sequence yield and quality observed as part of this workflow.

220

## 221 Conclusion

222 The approach and results described herein demonstrates a potential pathway for rapid clinical  
223 metagenomic sequencing diagnostics while highlighting several key challenges. The ability to  
224 collect and analyze sequence data in real time holds disruptive potential for the clinical diagnostics  
225 marketplace. However, this potential can only be fully met if the sample and library preparation  
226 methods are similarly permissive to rapid, high confidence analysis. This study suggests that it is  
227 possible to perform metagenomic classification on whole blood samples without unnecessary  
228 complexity in upfront processing methods (e.g., plasma isolation). Further, sequencing of enriched  
229 samples can commence in as little as 40 minutes from sample receipt. Utilizing a parallel targeted  
230 analysis pathway via PCR still permits analysis to occur in less than four hours. Perhaps the most  
231 significant limitation in analysis speed remains the time required to transmit data to the cloud or

232 physical storage for analysis – steps which could be separately enhanced by faster internet  
233 connections or greater local computational processing resources.

234

235 Based on the data presented here, achieving clinically relevant assay sensitivity appears to be a  
236 greater challenge than the accuracy of pathogen classification. While this study did not seek to  
237 perform a comprehensive limit of detection study on either the untargeted or targeted aspects of  
238 the workflow, it is clear that a significant amount of pathogen must be present in whole blood for  
239 detection to occur. Limits of detection for the workflow described herein likely fall within  $1 \times 10^5$   
240 to  $1 \times 10^6$  cells/mL for metagenomic shotgun sequencing, with limits of detection for targeted  
241 sequencing likely one to two logs lower. While these figures are in line with peak titer numbers  
242 for many clinical pathogens causative of bacteremia, including *Y. pestis*<sup>25</sup>, this assay could lead to  
243 false negatives at lower titers or earlier stages of infection. These limits of detection also focus  
244 solely on pathogen identification and the presence/absence of related plasmids; in contrast,  
245 pathogen characterization (i.e., identifying drug resistance genotype variants) requires  
246 significantly higher sequencing coverage for high confidence genotyping. Additional input DNA  
247 or sequencing time would be required to achieve sufficient coverage for these types of  
248 characterization, unless the regions of interest within specific pathogens were incorporated into  
249 the targeted portion of the workflow.

250

251 Overall, this study presents an important initial step toward rapid detection of clinical pathogens  
252 in human whole blood. However, it is clear that significant gains in sensitivity must be achieved  
253 through increased sequencing throughput or pathogen enrichment. Anticipated gains in sequencing

254 throughput communicated by ONT via chemistry improvements or parallel sequencing on larger  
255 platforms (e.g., GridION) should enhance sensitivity without substantially increasing sample-to-  
256 answer duration. Additional pathogen enrichment methods, such as plasma isolation to generate  
257 cell free fluids, or sequence capture, will also improve assay sensitivity<sup>26,27</sup>; However, these steps  
258 add additional time to sample processing and increase overall assay complexity, which may  
259 eventually limit the adoption of similar assays in laboratories which perform only CLIA-waived  
260 or moderately complex diagnostic tests. Software-based methods such as ONT's Read Until are  
261 perhaps the most promising method to increase sensitivity without increasing sample-to-answer  
262 time or per-sample cost by selectively rejecting host background sequence reads during  
263 sequencing<sup>28</sup>. Continued development and optimization of this and similar assays hold the promise  
264 that rapid human clinical pathogen diagnostics via non-targeted sequence genotype assays are on  
265 the horizon.

266

## 267 **Materials and Methods**

### 268 **Sample Preparation**

269 Human whole blood (lithium heparin anticoagulant) was obtained from BioreclamationIVT. *Y.*  
270 *pestis* strain Harbin 35 (NR-639) was obtained through BEI Resources. ZymoBIOMICS™  
271 Microbial Community Standards were obtained from Zymo Research and consisted of the  
272 following organisms: *Pseudomonas aeruginosa*, *Escherichia coli*, *Salmonella enterica*,  
273 *Lactobacillus fermentum*, *Enterococcus faecalis*, *Staphylococcus aureus*, *Listeria monocytogenes*,  
274 *Bacillus subtilis*, *Saccharomyces cerevisiae*, *Cryptococcus neoformans*. The concentrations of all  
275 cultures were determined via hemocytometer across three replicates. The *Y. pestis* stock had a

276 concentration of  $1.29 \times 10^8$  cells/mL and the Zymo mock community stock had a total  
277 concentration of  $2.42 \times 10^9$  total cells/mL (equivalent to approximately  $3 \times 10^8$  cells/mL of each  
278 bacterial species). To spike blood samples, the indicated concentration of bacterial culture was  
279 added to 500  $\mu$ L whole blood and vortexed gently for ~10 seconds.

280

## 281 Lysis and Nucleic Acid Purification

282 Sample lysis was performed with the OmniLyse (ClaremontBio) per manufacturer's instructions.  
283 The OmniLyse cartridge was pre-rinsed with approximately 500  $\mu$ L of molecular biology grade  
284 water (ThermoFisher) for one minute. Lysis of 250  $\mu$ L of human whole blood spiked with bacteria  
285 was performed for two minutes. Initial nucleic acid purification was performed via AMPure XP  
286 beads (BeckmanCoulter). An additional 1.8 volumes of beads were added to the lysed solution.  
287 After binding for 10 minutes at ambient temperature, the pellet was washed 3x with 500  $\mu$ L fresh  
288 70% ethanol. DNA was eluted in 40  $\mu$ L of molecular biology grade water. Purity and DNA  
289 concentration were measured via Nanodrop (ThermoFisher). Pathogen enrichment was carried out  
290 using the NEBNext® Microbiome DNA Enrichment Kit (New England Biolabs). MBD2-Fc beads  
291 were pre-incubated with Protein A beads prior to each experiment to reduce total assay time.  
292 Remaining enrichment steps followed manufacturer's protocol with final elution in 40  $\mu$ L of  
293 molecular biology grade water.

294

## 295 Amplification

296 Purified nucleic acid was subject to PCR using Phusion DNA polymerase (New England Biolabs).  
297 One  $\mu$ L of template DNA was added to each 50  $\mu$ L PCR reaction. Individual primer sets are listed

298 in Table S1. PCR products were purified using AMPure XP beads as per manufacturer instructions  
299 and eluted in 40  $\mu$ L molecular biology grade water. Concentrations were measured via Nanodrop.  
300 Products were later verified by gel electrophoresis (1% agarose in 1X TAE buffer). The PCR  
301 products were mixed to produce a cocktail with 1  $\mu$ g of total DNA (0.2 ng of each of five PCR  
302 products) for library preparation.

303

#### 304 MinION library preparation and sequencing

305 MinION library preparations were prepared according to the appropriate protocols. Genomic  
306 sequencing was performed using the Rapid Sequencing of genomic DNA kit (SQK-RAD002).  
307 Amplicon sequencing was performed using the 1D Amplicon Sequencing kit (SQK-LSK108). The  
308 maximum amount of input DNA volume (7.5  $\mu$ L) was added for rapid genomic sequencing; 1  $\mu$ g  
309 of total DNA was utilized as input for amplicon sequencing library preparation. Prepared libraries  
310 were loaded onto Spot-On flow cells (SpotON Flow Cell Mk I – R9.4). Amplicon libraries were  
311 added to the same flow cell 90-120 minutes after addition of the genomic library. The sequencer  
312 was reinitialized and run for an additional 6-24 hours depending on the sequencing run.  
313 Basecalling was performed using the local version of the albacore version 1.1.2 basecaller.

314

#### 315 Data analysis

316 Real time analysis was performed using the What's In My Pot (WIMP) tool provided by Oxford  
317 Nanopore Technology's Metrichor<sup>11</sup>. Basecalled reads were sampled based on sequencing time  
318 for comparative analysis between experiments as indicated. Reads binned according to pass and  
319 fail were combined prior to additional analysis. Poretools<sup>29</sup> version 0.6.0 was used to generate

320 fastq files for the MinION 1D reads. As WIMP does not contain a human reference in the database,  
321 One Codex<sup>5</sup> was used as a comparator and to properly identify host/background sequence.  
322 Sequence alignments were generated using Graphmap (v0.22)<sup>30</sup>. Resulting SAM alignment files  
323 were converted to BAM format using SAMtools (v1.4)<sup>31</sup>. Visual alignment of reads and  
324 confirmation of variant calls was performed using IGV version 2.3<sup>32</sup>. Reads were aligned against  
325 the *Yersinia pestis* biovar Medievalis strain Harbin 35 genome (accession number CP001608.1).

326

### 327 **Acknowledgements**

328 The authors would like to thank Oxford Nanopore Technologies for providing reagents for this  
329 work. The authors would also like to thank Dr. Charles Chiu for his technical input as part of this  
330 effort and the University of Texas Medical Branch for their recommendations on *Y. pestis* primers.  
331 The following reagent was obtained through BEI Resources, NIAID, NIH: *Yersinia pestis*, Strain  
332 Harbin 35, NR-639.

333

### 334 **Author Contributions**

335 Conceived and designed the experiments: FCH KLT DRK. Performed the experiments: FCH KS  
336 KLT. Analyzed the data: SLG FCH KLT. Wrote the paper: FCH SLG.

337

### 338 **Data Availability**

339 Raw DNA sequence reads have been deposited in the NCBI Sequence Read Archive under  
340 accession numbers SAMN07286086 and SAMN07286087.



341

342 **References**


- 343 1. Singh, R. R., Luthra, R., Routbort, M. J., Patel, K. P. & Medeiros, L. J. Implementation of  
344 next generation sequencing in clinical molecular diagnostic laboratories: advantages,  
345 challenges and potential. *Expert Rev. Precis. Med. Drug Dev.* **1**, 109–120 (2016).
- 346 2. Goldberg, B., Sichtig, H., Geyer, C., Ledebor, N. & Weinstock, G. M. Making the Leap from  
347 Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing  
348 in Infectious Disease Diagnostics. *mBio* **6**, e01888-15 (2015).
- 349 3. Wetterstrand, K. A. DNA Sequencing Costs: Data. *National Human Genome Research*  
350 *Institute (NHGRI)* Available at: [https://www.genome.gov/27541954/DNA-Sequencing-Costs-](https://www.genome.gov/27541954/DNA-Sequencing-Costs-Data)  
351 [Data](https://www.genome.gov/27541954/DNA-Sequencing-Costs-Data). (Accessed: 30th May 2017)
- 352 4. Mikheyev, A. S. & Tin, M. M. Y. A first look at the Oxford Nanopore MinION sequencer.  
353 *Mol. Ecol. Resour.* **14**, 1097–1102 (2014).
- 354 5. Brown, B. L., Watson, M., Minot, S. S., Rivera, M. C. & Franklin, R. B. MinION<sup>TM</sup> nanopore  
355 sequencing of environmental metagenomes: a synthetic approach. *GigaScience* (2017).  
356 doi:10.1093/gigascience/gix007
- 357 6. Walter, M. C. *et al.* MinION as part of a biomedical rapidly deployable laboratory. *J.*  
358 *Biotechnol.* doi:10.1016/j.jbiotec.2016.12.006
- 359 7. Schmidt, K. *et al.* Identification of bacterial pathogens and antimicrobial resistance directly  
360 from clinical urines by nanopore-based metagenomic sequencing. *J. Antimicrob. Chemother.*  
361 dkw397 (2016). doi:10.1093/jac/dkw397
- 362 8. Greninger, A. L. *et al.* Rapid metagenomic identification of viral pathogens in clinical  
363 samples by real-time nanopore sequencing analysis. *Genome Med.* **7**, 99 (2015).

- 364 9. Jain, M. *et al.* Nanopore sequencing and assembly of a human genome with ultra-long reads.  
365 *bioRxiv* 128835 (2017). doi:10.1101/128835
- 366 10. Edwards, A. *et al.* Deep Sequencing: Intra-Terrestrial Metagenomics Illustrates The  
367 Potential Of Off-Grid Nanopore DNA Sequencing. *bioRxiv* 133413 (2017).  
368 doi:10.1101/133413
- 369 11. Juul, S. *et al.* What's in my pot? Real-time species identification on the MinION. *bioRxiv*  
370 030742 (2015). doi:10.1101/030742
- 371 12. Loonen, A. J. M. *et al.* Comparison of pathogen DNA isolation methods from large  
372 volumes of whole blood to improve molecular diagnosis of bloodstream infections. *PloS One*  
373 **8**, e72349 (2013).
- 374 13. Horz, H.-P., Scheer, S., Huenger, F., Vianna, M. E. & Conrads, G. Selective isolation of  
375 bacterial DNA from human clinical specimens. *J. Microbiol. Methods* **72**, 98–102 (2008).
- 376 14. Maps and Statistics | Plague | CDC. Available at: <https://www.cdc.gov/plague/maps/>.  
377 (Accessed: 23rd May 2017)
- 378 15. Califf, K. J., Keim, P. S., Wagner, D. M. & Sahl, J. W. Redefining the differences in gene  
379 content between *Yersinia pestis* and *Yersinia pseudotuberculosis* using large-scale  
380 comparative genomics. *Microb. Genomics* **1**, (2015).
- 381 16. Duan, R. *et al.* Homology Analysis of Pathogenic *Yersinia* Species *Yersinia*  
382 *enterocolitica*, *Yersinia pseudotuberculosis*, and *Yersinia pestis* Based on Multilocus  
383 Sequence Typing. *J. Clin. Microbiol.* **52**, 20–29 (2014).
- 384 17. Vutukuru, M. R. *et al.* A rapid, highly sensitive and culture-free detection of pathogens  
385 from blood by positive enrichment. *J. Microbiol. Methods* **131**, 105–109 (2016).

- 386 18. Capuano, F., Mülleder, M., Kok, R., Blom, H. J. & Ralser, M. Cytosine DNA  
387 Methylation Is Found in *Drosophila melanogaster* but Absent in *Saccharomyces cerevisiae*,  
388 *Schizosaccharomyces pombe*, and Other Yeast Species. *Anal. Chem.* **86**, 3697–3702 (2014).
- 389 19. Tiner, B. L. *et al.* Combinational deletion of three membrane protein-encoding genes  
390 highly attenuates *Yersinia pestis* while retaining immunogenicity in a mouse model of  
391 pneumonic plague. *Infect. Immun.* **83**, 1318–1338 (2015).
- 392 20. Ponnusamy, D. *et al.* High-throughput, signature-tagged mutagenic approach to identify  
393 novel virulence factors of *Yersinia pestis* CO92 in a mouse model of infection. *Infect. Immun.*  
394 **83**, 2065–2081 (2015).
- 395 21. Sha, J. *et al.* Characterization of an F1 deletion mutant of *Yersinia pestis* CO92,  
396 pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity  
397 and specificity of F1 antigen capture-based dipsticks. *J. Clin. Microbiol.* **49**, 1708–1715  
398 (2011).
- 399 22. Sha, J. *et al.* Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role  
400 of Lpp in inducing bubonic and pneumonic plague. *Infect. Immun.* **76**, 1390–1409 (2008).
- 401 23. Buchrieser, C. *et al.* The 102-kilobase *pgm* locus of *Yersinia pestis*: sequence analysis  
402 and comparison of selected regions among different *Yersinia pestis* and *Yersinia*  
403 *pseudotuberculosis* strains. *Infect. Immun.* **67**, 4851–4861 (1999).
- 404 24. Jain, M., Olsen, H. E., Paten, B. & Akeson, M. The Oxford Nanopore MinION: delivery  
405 of nanopore sequencing to the genomics community. *Genome Biol.* **17**, 239 (2016).
- 406 25. Bosio, C. F., Jarrett, C. O., Gardner, D. & Hinnebusch, B. J. Kinetics of Innate Immune  
407 Response to *Yersinia pestis* after Intradermal Infection in a Mouse Model. *Infect. Immun.* **80**,  
408 4034–4045 (2012).


- 409 26. Grumaz, S. *et al.* Next-generation sequencing diagnostics of bacteremia in septic patients.  
410 *Genome Med.* **8**, 73 (2016).
- 411 27. Gasc, C., Peyretailade, E. & Peyret, P. Sequence capture by hybridization to explore  
412 modern and ancient genomic diversity in model and nonmodel organisms. *Nucleic Acids Res.*  
413 **44**, 4504–4518 (2016).
- 414 28. Loose, M., Malla, S. & Stout, M. Real-time selective sequencing using nanopore  
415 technology. *Nat. Methods* **13**, 751–754 (2016).
- 416 29. Loman, N. J. & Quinlan, A. R. Poretools: a toolkit for analyzing nanopore sequence data.  
417 *Bioinforma. Oxf. Engl.* **30**, 3399–3401 (2014).
- 418 30. Sović, I. *et al.* Fast and sensitive mapping of nanopore sequencing reads with GraphMap.  
419 *Nat. Commun.* **7**, 11307 (2016).
- 420 31. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
421 2078–2079 (2009).
- 422 32. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
- 423 33. Laurence, M., Hatzis, C. & Brash, D. E. Common Contaminants in Next-Generation  
424 Sequencing That Hinder Discovery of Low-Abundance Microbes. *PLOS ONE* **9**, e97876  
425 (2014).

426




427

428 Fig 1. Workflow Overview. Production of a rapid workflow which includes modular enrichment  
429 steps (methylation-based enrichment, PCR). The workflow is compatible with small blood draw  
430 volumes (<250  $\mu$ L). Real time analysis of shotgun sequencing data commences within  
431 approximately 40 minutes of sample receipt. Targeted detection commences within 2-4 hours  
432 dependent on the duration of target-specific PCR.




433

434 Fig 2. Detection of Pathogens in Whole Blood Requires Host Depletion. A) Metagenomic  
435 classification from shotgun sequence data of pathogens present in whole blood is significantly  
436 enhanced by depletion of host sequence. 0.66% of total reads are classified as *Yersinia* following  
437 sequence enrichment, compared to 0.023% of total reads when enrichment is not utilized  
438 corresponding to a 28-fold increase in the abundance of pathogen sequence. B) Representative  
439 detection of all species included in the Zymo mock community via shotgun sequencing and  
440 metagenomic classification following enrichment. Significant abundance of *E. coli* is likely due to  
441 laboratory contamination<sup>33</sup>.




443 Fig 3. Hybrid Assay Provides Enhanced Pathogen-Specific Sensitivity without Compromising  
444 Detection of Background Pathogens. A) Total read count across duration of a hybrid workflow.  
445 Relatively few reads captured during the non-targeted portion of the assay (Time 0-1.6 hours) with  
446 significant increase in total read counts following the addition of the amplicon library. B)  
447 Metagenomic classification via WIMP following hybrid workflow. The majority of *Yersinia* reads  
448 are based on amplicon sequencing. Bacteria and fungi present in the Zymo mock community were  
449 identified as part of the genomic sequencing portion of the workflow. C) Representative  
450 visualization of reads aligned to the Harbin 35 reference genome. Significant depth of coverage of  
451 the amplicon sequence (> 1,000x coverage) observed at the expected location within the *Y. pestis*  
452 genome. Non-targeted sequences are also shown, interspersed across the genome at low coverage.





454 Fig 4. Visualizing Key Variants for Strain Identification. A) NC\_017265.1:2,998,385. Mixture of  
455 T (26% of total reads, which corresponds to the reference genome) and G (71% of total reads,  
456 which corresponds to other *Y. pestis* strains including CO92). B) NC\_017265.1:4,279,948.  
457 Majority of reads conform to the reference genome. Certain *Y. pestis* strains (e.g., Kim 10) contain  
458 a deletion of this base.



459

460 Fig 5. Relative Quality Scores between Transposase- and Ligation-Based Library Preparation

461 Approaches. A) Quality scores resulting from the rapid genomic library prep sequencing kit. B)

462 Quality scores resulting from the complete hybrid workflow.